Emergent Biosolutions Inc. (NYSE:EBS) Receives Consensus Rating of “Hold” from Brokerages

Emergent Biosolutions Inc. (NYSE:EBS) has received an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.00.

EBS has been the subject of several research reports. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd.

Insider Activity at Emergent Biosolutions

In other news, Director Donald W. Degolyer sold 15,481 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $130,040.40. Following the completion of the transaction, the director directly owned 129,721 shares of the company’s stock, valued at $1,089,656.40. This trade represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn C. Zoon sold 17,202 shares of Emergent Biosolutions stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $144,496.80. Following the completion of the transaction, the director owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. This trade represents a 17.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,925 shares of company stock worth $543,512 in the last ninety days. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EBS. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions during the second quarter valued at about $31,000. Torren Management LLC purchased a new stake in Emergent Biosolutions in the 4th quarter worth approximately $37,000. CANADA LIFE ASSURANCE Co bought a new position in Emergent Biosolutions in the 4th quarter valued at $45,000. Raymond James Financial Inc. bought a new position in Emergent Biosolutions in the 2nd quarter valued at $53,000. Finally, Farther Finance Advisors LLC grew its position in shares of Emergent Biosolutions by 361.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 4,827 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Price Performance

Emergent Biosolutions stock opened at $7.67 on Wednesday. Emergent Biosolutions has a 12 month low of $5.61 and a 12 month high of $14.06. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The business’s 50 day simple moving average is $8.20 and its 200 day simple moving average is $9.24. The company has a market cap of $395.51 million, a price-to-earnings ratio of -27.37 and a beta of 2.34.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.